Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Assets (2020 - 2025)

Cytek Biosciences' Assets history spans 6 years, with the latest figure at $461.5 million for Q4 2025.

  • For Q4 2025, Assets fell 7.6% year-over-year to $461.5 million; the TTM value through Dec 2025 reached $461.5 million, down 7.6%, while the annual FY2025 figure was $461.5 million, 7.6% down from the prior year.
  • Assets reached $461.5 million in Q4 2025 per CTKB's latest filing, down from $494.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $525.1 million in Q2 2023 to a low of $230.3 million in Q2 2021.
  • Average Assets over 5 years is $479.4 million, with a median of $492.8 million recorded in 2022.
  • Peak YoY movement for Assets: surged 114.01% in 2022, then fell 7.87% in 2024.
  • A 5-year view of Assets shows it stood at $463.3 million in 2021, then rose by 12.12% to $519.5 million in 2022, then fell by 4.82% to $494.5 million in 2023, then increased by 1.02% to $499.5 million in 2024, then dropped by 7.6% to $461.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Assets are $461.5 million (Q4 2025), $494.9 million (Q3 2025), and $493.3 million (Q2 2025).